东方生物
(688298)
| 流通市值：43.59亿 | | | 总市值：43.59亿 |
| 流通股本：2.02亿 | | | 总股本：2.02亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 256,264,814.4 | 947,379,903.5 | 671,812,093.43 | 403,079,827.49 |
| 营业收入 | 256,264,814.4 | 947,379,903.5 | 671,812,093.43 | 403,079,827.49 |
| 二、营业总成本 | 346,307,060.81 | 1,341,786,186.68 | 898,681,964.69 | 582,106,668.08 |
| 营业成本 | 146,343,305.53 | 560,899,414.12 | 392,089,040.09 | 251,445,125.23 |
| 税金及附加 | 4,781,421.33 | 19,874,555.65 | 10,573,098.29 | 7,503,101.95 |
| 销售费用 | 42,942,552.49 | 190,988,640.32 | 133,863,869.99 | 88,636,643.32 |
| 管理费用 | 92,700,153.02 | 402,307,015.1 | 271,240,920.05 | 180,870,212.14 |
| 研发费用 | 42,007,384.36 | 230,811,644.92 | 163,552,038.82 | 113,676,614.38 |
| 财务费用 | 17,532,244.08 | -63,095,083.43 | -72,637,002.55 | -60,025,028.94 |
| 其中:利息费用 | 2,515,595.17 | 9,908,990.32 | 7,490,870.56 | 5,446,990.74 |
| 其中:利息收入 | 32,802,993.74 | 80,351,790.22 | 70,570,633.38 | 47,503,779.51 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 3,038,506.56 | -1,596,613.77 | 4,987,783.59 | 4,992,565.99 |
| 加:投资收益 | 7,098,406.57 | 8,681,541.5 | 5,520,335.43 | 3,484,332.15 |
| 净敞口套期收益 | - | 0 | - | - |
| 汇兑收益 | - | 0 | - | - |
| 资产处置收益 | 573,989.4 | 1,748,605.93 | 1,678,614.11 | 1,741,743.14 |
| 资产减值损失(新) | -11,642,070.82 | -199,366,343.14 | -16,473,020.48 | -13,924,362.69 |
| 信用减值损失(新) | -4,004,163.41 | -7,919,960.07 | -6,271,653.33 | 1,285,084.69 |
| 其他收益 | 2,161,269.36 | 10,614,265.82 | 3,211,237.36 | 2,499,448.77 |
| 四、营业利润 | -92,816,308.75 | -582,244,786.91 | -234,216,574.58 | -178,948,028.54 |
| 加:营业外收入 | 2,826.09 | 776,755.75 | 299,801.03 | 279,794.97 |
| 减:营业外支出 | 12,404.11 | 2,025,806.33 | 806,307.95 | -5,558,467.63 |
| 五、利润总额 | -92,825,886.77 | -583,493,837.49 | -234,723,081.5 | -173,109,765.94 |
| 减:所得税费用 | 5,875,309.3 | 13,911,370.06 | -3,548,893.96 | 950,032.13 |
| 六、净利润 | -98,701,196.07 | -597,405,207.55 | -231,174,187.54 | -174,059,798.07 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -98,701,196.07 | -597,405,207.55 | -231,174,187.54 | -174,059,798.07 |
| 终止经营净利润 | - | 0 | - | - |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -93,843,129.17 | -573,598,190.08 | -212,632,127.27 | -163,097,778.95 |
| 少数股东损益 | -4,858,066.9 | -23,807,017.47 | -18,542,060.27 | -10,962,019.12 |
| 扣除非经常损益后的净利润 | -105,413,891.47 | -597,472,097.82 | -231,972,814.13 | -184,157,052.42 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.49 | -2.98 | -1.1 | -0.84 |
| (二)稀释每股收益 | -0.49 | -2.98 | -1.1 | -0.84 |
| 八、其他综合收益 | -4,955,418.9 | -28,782,723.77 | -21,790,105.27 | -21,826,549.14 |
| 归属于母公司股东的其他综合收益 | -4,955,418.9 | -28,782,723.77 | -21,790,105.27 | -21,826,549.14 |
| 九、综合收益总额 | -103,656,614.97 | -626,187,931.32 | -252,964,292.81 | -195,886,347.21 |
| 归属于母公司股东的综合收益总额 | -98,798,548.07 | -602,380,913.85 | -234,422,232.54 | -184,924,328.09 |
| 归属于少数股东的综合收益总额 | -4,858,066.9 | -23,807,017.47 | -18,542,060.27 | -10,962,019.12 |
| 公告日期 | 2026-04-29 | 2026-04-29 | 2025-10-31 | 2025-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |